In drug development, AI accelerates discovery by mapping synthetic lethality (e.g., BRCA/PARP), simulating protein folding (e.g., AlphaFold), and optimizing synergistic combinations such as PI3K inhibitors in hormone-receptor-positive BC [308,313]. Here, NR4A1 is linked to breast cancer.